Target Group is a small Canadian cannabis company focused on cultivating, processing, and distributing cannabis in both the medical and adult-use recreational markets. Its core asset is Canary Rx, a licensed indoor grow facility in Simcoe, Ontario with annual licensed production capacity of roughly 3,600 kg of dried flower. Rather than building a direct-to-consumer retail brand, Target Group focuses on wholesale cannabis sales and co-packaging services for other cannabis brands. The company also holds an exclusive global distribution and licensing agreement with Serious Seeds, covering a collection of well-known strains including AK-47, Chronic, and White Russian, in exchange for royalties on gross sales. Target Group's product portfolio includes cannabis flower, pre-rolls, vape pods, infused beverages, edibles, and CBD wellness products. The Wisp vaporizer system — a single-use pre-measured pod format acquired via CannaKorp — is intended to move the company up the value chain from commodity flower into higher-margin branded consumer products. Co-packaging services add a fee-based revenue stream that leverages the facility's licensed infrastructure. A notable structural feature is a related-party debt arrangement with CL Investors, a company connected to Target Group's CEO, which requires repayment of the greater of fixed amounts or 50% of net revenue annually, and includes options to acquire up to 100% of subsidiary equity, creating meaningful dilution risk for public shareholders.